Impact Journals, a prominent publisher recognized for its commitment to rapid dissemination of biomedical discoveries, has once again confirmed its sponsorship of the Open Access Team participating in the 2025 Ride for Roswell. This annual event, held on June 28, 2025, in Buffalo, New York, stands as one of the nation’s foremost cycling fundraisers dedicated to advancing cancer research. By intertwining the spheres of scientific publishing and community engagement, Impact Journals exemplifies how academic institutions and the public can collaboratively drive progress toward the eradication of cancer.

The Ride for Roswell, hosted by the esteemed Roswell Park Comprehensive Cancer Center, has garnered national attention for its comprehensive approach to cancer advocacy. It mobilizes thousands of riders, volunteers, and supporters from across the United States to not only raise crucial funds for scientific research but also to foster awareness and support for survivors and families impacted by cancer. The 2025 ride features nine distinct routes, ranging from a modest 4-mile journey to a grueling 100-mile challenge, all originating from the University at Buffalo North Campus, thereby accommodating participants of varying skill levels and dedication.

Central to the impact of this event is the Open Access Team, a collective underscored by a profound commitment to open scientific communication. Led by team captain Sergei Kurenov, the team symbolizes the intersection of medical science, publishing innovation, and patient advocacy. Their sponsorship by Impact Journals highlights a unique synergy, wherein open access publishing platforms not only accelerate the dissemination of cutting-edge cancer research but also actively participate in community-driven fundraising and awareness initiatives.

Open access publishing has revolutionized how scientific information is shared by removing traditional paywalls, thereby democratizing access to knowledge that can expedite breakthroughs in cancer treatment and prevention. Impact Journals, through its suite of open access publications including Oncotarget, Aging, Genes & Cancer, and Oncoscience, facilitates rapid peer review and immediate availability of research findings to a global audience. This model is essential for translational science where timely data sharing can influence clinical decision-making and policy development.

The team’s dedication gains a personal dimension through captain Sergei Kurenov’s reflections on his motivation. Having witnessed firsthand the challenges posed by cancer, including his father’s battle and the resilience of friends facing prostate and lung cancers, Kurenov channels these experiences into a decade-long commitment to this cause. His participation underscores a critical aspect of the event’s narrative: that beyond scientific innovation, cancer research is deeply human and requires sustained empathy and advocacy.

This year’s ride carries a poignant tribute to Dr. Mikhail (Misha) Blagosklonny, a visionary scientist whose pioneering research and leadership reshaped the landscapes of oncology and gerontology. Dr. Blagosklonny’s elucidation of mTOR signaling pathways and his advocacy for pharmacological interventions such as rapamycin have opened new horizons in understanding cellular aging and cancer proliferation mechanisms. His role as founding Editor-in-Chief of Oncotarget, Aging, and Oncoscience also marked significant strides in championing open access publishing, ensuring scientific knowledge remains freely accessible and widely disseminated.

The Ride for Roswell’s multiple route options not only test physical endurance but symbolize the multifaceted approach necessary to combat cancer. Scientific advancements require collaboration among diverse disciplines, from molecular biology and immunotherapy to epidemiology and bioinformatics. Events like this facilitate public involvement and underscore the essentiality of sustained funding streams for complex cancer research initiatives.

Support for the Open Access Team can be rendered via donations, team membership, or storytelling contributions, engaging a wide spectrum of stakeholders. This inclusive platform fosters communal responsibility and empowers individuals to participate actively in the protracted battle against cancer. Such participation ensures that cancer research funding does not remain siloed within academic or clinical settings but permeates public consciousness.

Impact Journals’ involvement exemplifies a broader paradigm shift within scientific publishing—where publishers are not merely passive conduits of information but active participants in research ecosystems and community outreach. The synergy between open access platforms and grassroots fundraising amplifies the reach and impact of cancer research endeavors.

With the 2025 Ride for Roswell poised to mobilize riders from around the country and beyond, the event represents a microcosm of the global commitment to improving cancer outcomes. The visibility afforded by such collaborations between publishers, researchers, and the community serves to accelerate the implementation of novel therapies, enhance patient education, and ultimately move society towards a future free of cancer’s burden.

Prospective participants and supporters are encouraged to visit the rally’s official channels to contribute toward this vital cause. Through the combined forces of science, philanthropy, and community spirit, tangible strides can be achieved in unraveling the complexities of cancer biology and delivering innovative solutions.

To explore more about the journals leading this transformative charge in biomedical publishing, and to learn how timely access to research fuels discoveries, interested readers can visit ImpactJournals.com. For direct communication or media engagements, Impact Journals remains accessible via media@impactjournals.com, continuing its transparent and collaborative ethos.

Subject of Research:
Article Title:
News Publication Date: June 10, 2025
Web References:
https://rideforroswell.org/
https://www.roswellpark.org/
https://give.roswellpark.org/site/TR/SpecialEvents/General?team_id=23320&pg=team&fr_id=2020
https://www.oncotarget.com/
https://www.aging-us.com/
https://www.genesandcancer.com/
https://www.oncoscience.us/
http://impactjournals.com/
References:
Image Credits: Impact Journals ® is a registered trademark of Rapamycin Press LLC
Keywords: Cancer research, Cancer, Diseases and disorders, Health and medicine, Open access, Publishing industry, Digital publishing, Academic publishing, Scientific community, Scientific publishing

The essence of CAR T-cell therapy lies in the genetic reprogramming of a patient’s T cells, a vital subset of white blood cells responsible for immune defense. These T cells are harvested from the patient’s bloodstream and transported to a state-of-the-art laboratory, where viral vectors are employed to insert synthetic receptors—termed chimeric antigen receptors (CARs)—that enable these cells to specifically identify and bind to antigens expressed on tumor cells. This molecular engineering effectively equips the immune cells with enhanced targeting capabilities, creating a highly personalized and potent cancer-fighting army once reintroduced into the patient.

Such intricate cellular processing demands the sophisticated infrastructure available at the Roswell Park GMP Engineering & Cell Manufacturing Facility (GEM), one of the most expansive and advanced cleanroom complexes of its kind in the nation. Spanning two buildings and equipped with 20 sterile production rooms, GEM facilitates the rapid yet meticulous expansion and quality control of CAR T cells. This facility is critical not only for accelerating the production timeline but also for ensuring compliance with stringent regulatory standards required for cell therapies, thus enabling broader access for patients.

Roswell Park’s commitment extends beyond manufacturing, with teams of scientists, oncologists, and engineers relentlessly working to refine the safety and efficacy profiles of CAR T-cell therapies. Continuous advancements aim to mitigate adverse effects such as cytokine release syndrome and neurotoxicity, which can arise from the robust immune activation caused by these modified cells. Recent protocol improvements and enhanced patient monitoring have substantially increased the therapeutic window, making CAR T-cell therapy a viable option for an expanding group of cancer patients.

The clinical outcomes achieved by these therapies at Roswell Park are remarkable, especially in hematologic malignancies. Data indicate remission rates exceeding 50% in various lymphomas and approaching an astonishing 90% in certain leukemias. These figures mark a dramatic improvement over traditional treatments and underscore the potential of CAR T-cell therapy to induce sustained remission, fundamentally altering the disease trajectory for patients previously facing limited prospects.

A poignant example is the case of Chris Vogelsang, a 70-year-old patient who battled an aggressive form of lymphoma over fourteen years, enduring multiple interventions including stem cell transplantation. After recurrent relapses and deteriorating health, CAR T-cell therapy offered a lifeline. Since his treatment in 2022 and subsequent remission confirmed in 2023, Vogelsang has regained vitality and resumed activities such as tennis, symbolizing the therapy’s profound impact not only on survival but on quality of life.

CAR T-cell therapy’s mechanism is rooted in advanced immunology and genetic engineering principles. By harnessing viral vectors—commonly lentiviruses or retroviruses—scientists introduce CAR genes into the patient’s T cells. These synthetic receptors combine antigen recognition domains, typically derived from monoclonal antibodies, with intracellular T-cell activating motifs. This design enables the engineered T cells to both recognize malignant cells lacking the classical major histocompatibility complex (MHC) markers and elicit a robust immune response, circumventing mechanisms cancer cells use to evade immune detection.

The manufacturing pipeline proceeds through several complex stages, starting with leukapheresis—the extraction of white blood cells—followed by activation and transduction of T cells, expansion in bioreactors, rigorous quality testing, and finally cryopreservation prior to infusion. Each step is meticulously monitored to maintain cell viability, potency, and purity. Roswell Park’s GEM facility’s scale and modularity are instrumental in meeting both investigational and commercial demands, facilitating a future when such therapies become more commonplace.

Current regulatory approvals of CAR T-cell therapies predominantly cover hematologic cancers such as diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and mantle cell lymphoma. However, ongoing research at Roswell Park and globally is pushing boundaries toward solid tumors, where challenges include the immunosuppressive tumor microenvironment and antigen heterogeneity. Innovations in receptor design, combination therapies, and gene editing techniques hold promise to overcome these barriers.

The multidisciplinary teams at Roswell Park also focus on translational research to enhance therapeutic durability and overcome resistance. Investigating mechanisms of relapse, immune escape, and optimizing cell persistence post-infusion remain active areas of study. Their aim is to develop next-generation CAR constructs with improved specificity, safety switches to control adverse events, and combinatorial targeting strategies.

As CAR T-cell therapy gradually moves from an experimental to a standard-of-care approach, educating clinicians, patients, and the public about its capabilities and accessibility is critical. Roswell Park’s efforts, including comprehensive patient education and advanced clinical trials, are critical in shaping the future landscape of personalized cancer immunotherapy. Their GMP facility exemplifies the integration of cutting-edge science and patient-centric care, underlining a new era of hope and innovation in oncology.

For more information about Roswell Park’s CAR T-cell therapy programs and their GMP Engineering & Cell Manufacturing Facility, interested individuals can visit the center’s dedicated webpage, which details treatment options, research developments, and patient resources. With continued progress, the vision of widely available, curative cellular therapies for an array of cancers moves closer to reality.

Subject of Research: People
Article Title: Roswell Park Advances CAR T-cell Therapy as a Groundbreaking Treatment for Blood Cancers
News Publication Date: April 17, 2025
Web References:

• https://www.roswellpark.org/
• https://roswellpark.org/gmp
• https://www.sciencedirect.com/science/article/pii/S0304383524002647
  Image Credits: Credit: All multimedia is available for free courtesy of Roswell Park Comprehensive Cancer Center
  Keywords: Blood cancer, Lymphoma, Cancer relapse, Cancer immunotherapy